Engineering therapeutic monoclonal antibodies
- PMID: 18363992
- DOI: 10.1111/j.1600-065X.2008.00601.x
Engineering therapeutic monoclonal antibodies
Abstract
During last two decades, the chimerization and humanization of monoclonal antibodies (mAbs) have led to the approval of several for the treatment of cancer, autoimmune diseases, and transplant rejection. Additional approaches have been used to further improve their in vivo activity. These include combining them with other modalities such as chemotherapy and redesigning them for improved pharmacokinetics, effector function, and signaling activity. The latter has taken advantage of new insights emerging from an increased understanding of the cellular and molecular mechanisms that are involved in the interaction of immunoglobulin G with Fc receptors and complement as well as the negative signaling resulting from the hypercrosslinking of their target antigens. Hence, mAbs have been redesigned to include mutations in their Fc portions, thereby endowing them with enhanced or decreased effector functions and more desirable pharmacokinetic properties. Their valency has been increased to decrease their dissociation rate from cells and enhance their ability to induce apoptosis and cell cycle arrest. In this review we discuss these redesigned mAbs and current data concerning their evaluation both in vitro and in vivo.
Similar articles
-
Target therapy of cancer: implementation of monoclonal antibodies and nanobodies.Hum Antibodies. 2009;18(3):81-100. doi: 10.3233/HAB-2009-0204. Hum Antibodies. 2009. PMID: 19729803 Review.
-
Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.Cancer Res. 2008 Oct 1;68(19):8049-57. doi: 10.1158/0008-5472.CAN-08-2268. Cancer Res. 2008. PMID: 18829563
-
Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.Cancer Res. 2007 Sep 15;67(18):8882-90. doi: 10.1158/0008-5472.CAN-07-0696. Cancer Res. 2007. PMID: 17875730
-
Selection, design, and engineering of therapeutic antibodies.J Allergy Clin Immunol. 2005 Oct;116(4):731-6; quiz 737. doi: 10.1016/j.jaci.2005.08.003. J Allergy Clin Immunol. 2005. PMID: 16210043 Review.
-
Engineering mouse monoclonal antibodies for cancer immunotherapy.Year Immunol. 1993;7:69-73. Year Immunol. 1993. PMID: 8372514 Review. No abstract available.
Cited by
-
Dengue virus neutralizing antibody: a review of targets, cross-reactivity, and antibody-dependent enhancement.Front Immunol. 2023 Jun 2;14:1200195. doi: 10.3389/fimmu.2023.1200195. eCollection 2023. Front Immunol. 2023. PMID: 37334355 Free PMC article. Review.
-
SILAC-based quantitative proteomics and microscopy analysis of cancer cells treated with the N-glycolyl GM3-specific anti-tumor antibody 14F7.Front Immunol. 2022 Nov 9;13:994790. doi: 10.3389/fimmu.2022.994790. eCollection 2022. Front Immunol. 2022. PMID: 36439103 Free PMC article.
-
Potential Therapeutic Targets for Combination Antibody Therapy against Pseudomonas aeruginosa Infections.Antibiotics (Basel). 2021 Dec 14;10(12):1530. doi: 10.3390/antibiotics10121530. Antibiotics (Basel). 2021. PMID: 34943742 Free PMC article. Review.
-
The reduced form of the antibody CH2 domain.Protein Sci. 2021 Sep;30(9):1895-1903. doi: 10.1002/pro.4142. Epub 2021 Jun 16. Protein Sci. 2021. PMID: 34107549 Free PMC article.
-
Inhibitory Monoclonal Antibodies and Their Recombinant Derivatives Targeting Surface-Exposed Carbonic Anhydrase XII on Cancer Cells.Int J Mol Sci. 2020 Dec 10;21(24):9411. doi: 10.3390/ijms21249411. Int J Mol Sci. 2020. PMID: 33321910 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
